Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers
2012 ◽
Vol 52
(7)
◽
pp. 1007-1016
◽
Keyword(s):
2008 ◽
Vol 48
(4)
◽
pp. 418-427
◽
2012 ◽
Vol 172
(4)
◽
pp. 366
◽
Keyword(s):
Keyword(s):
2000 ◽
Vol 12
(1)
◽
pp. 22-32
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):